Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
109.02(c) 109.78(c) 112.45(c) 111.63(c) 110.52(c) Last
6 334 195 6 114 537 9 821 321 8 268 761 9 183 777 Volume
+1.63% +0.70% +2.43% -0.73% -0.99% Change
More quotes
Financials (USD)
Sales 2020 45 641 M - -
Net income 2020 11 674 M - -
Net Debt 2020 75 457 M - -
P/E ratio 2020 27,0x
Yield 2020 4,31%
Sales 2021 53 996 M - -
Net income 2021 17 266 M - -
Net Debt 2021 63 358 M - -
P/E ratio 2021 13,0x
Yield 2021 4,67%
Capitalization 195 B 195 B -
EV / Sales 2020 5,93x
EV / Sales 2021 4,79x
Nbr of Employees 47 000
Free-Float 98,5%
More Financials
Company
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn‚'Ts disease, thyroid disease, Parkinson‚'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Sales are distributed geographically as follows: the United States (71.9%), Japan (3.7%), Germany... 
Sector
Pharmaceuticals
Calendar
01/22Earnings Release
More about the company
Notations Surperformance© of AbbVie Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ABBVIE INC.
01/15ABBVIE : Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neur..
PR
01/14ABBVIE INC. : Ex-dividend day for
FA
01/13SECTOR UPDATE : Health Care Stocks Rise in Cautious Wednesday Trade
MT
01/13SECTOR UPDATE : Health Care Stocks Maintaining Moderate Advance
MT
01/13GENMAB A/S : to Receive $40 Million Milestone Payment From AbbVie
MT
01/13HARPOON THERAPEUTICS : FDA Grants Orphan Drug Status to Harpoon Therapeutics, Ab..
MT
01/12ABBVIE : J.P. Morgan Healthcare Conference Presentation 985.1 KB
PU
01/12ABBVIE INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
01/12ABBVIE : Unit Allergan Enters Into Option to Buy Cypris Medical
MT
01/12ABBVIE : Allergan Aesthetics Enters Into Option to Acquire Cypris Medical
PR
01/12ABBVIE : Licenses First Drug Candidate From Collaboration With Dragonfly Therape..
MT
01/12ABBVIE : to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call
PR
01/12ABBVIE : Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immuno..
PR
01/07ABBVIE : Skyrizi Phase 3 Crohn's Induction Studies Meet Main Endpoints
DJ
01/07ABBVIE : Reports Positive Results From Phase 3 Studies of Risankizumab to Treat ..
MT
More news
News in other languages on ABBVIE INC.
2020Novartis-Tochter Sandoz erhält in Kanada Zulassung für Biosimilar Hyrimoz
2020ROCHE : Santé Canada approuve une association de Venclexta contre la leucémie
2020Roche und Partner AbbVie erhalten kanadische Zulassung für Venclexta
2020ROCHE : Daten bestätigen Vorteile von Venclexta-Kombiation bei CLL
2020ROCHE : des données avec Venclexta confirment l'efficacité pour la CLL
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 115,91 $
Last Close Price 110,52 $
Spread / Highest target 22,1%
Spread / Average Target 4,88%
Spread / Lowest Target -12,2%
EPS Revisions
Managers and Directors
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.3.15%195 120
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993